Clinical trials: Virus Diseases
HIV Infections
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1.
- Trial name
- NCT00350272
- Testing
- Elvucitabine, Lamivudine, Tenofovir
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 76 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis B Virus
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg one daily (OD) taken together vs.
- Trial name
- NCT00805675
- Testing
- Telbivudine, Tenofovir, Telbivudine plus tenofovir
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.
- Trial name
- NCT04774107
- Testing
- P1101 + Ribavirin
- Where
- 5 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- PharmaEssentia
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04690595
- Testing
- BAFFR-CAR T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- PeproMene Bio, Inc.
Prevention From Norovirus Infection
Norovirus Bivalent-Vaccine Efficacy Study
The purpose of this study is to determine whether the norovirus vaccine is effective in preventing acute gastroenteritis due to the experimental human Norovirus GII.4 challenge dose.
- Trial name
- NCT01609257
- Testing
- Norovirus Bivalent Vaccine, Saline Comparator
- Where
- 5 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Takeda
Chronic Hepatitis B
A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
This study is designed to assess safety, tolerability, and PK of single ascending doses (SAD) of ABI-4334 in Part A and multiple-ascending doses (MAD) of ABI-4334 in Part B in healthy subjects.
- Trial name
- NCT05569941
- Testing
- ABI-4334 Tablet
- Where
- New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Hepatitis D, Chronic
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD).
- Trial name
- NCT02732639
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a
- Where
- 7 sites in Romania
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Varicella
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of valaciclovir in pediatric patients with chickenpox
- Trial name
- NCT01390857
- Testing
- Valaciclovir
- Volunteers
- 379 people
- Sponsor
- GlaxoSmithKline
COVID-19
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
Evaluation of novel coronavirus induced severe pneumonia by dental pulp mesenchymal stem cells
- Trial name
- NCT04302519
- Testing
- Dental pulp mesenchymal stem cells
- Volunteers
- 24 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Chronic Hepatitis B
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.
- Trial name
- NCT02287857
- Testing
- Domestic Tenofovir Disoproxil Fumarate Tablets, Tenofovir Disoproxil Fumarate Tablets of Gilead
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Influenza
Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population
This is a laboratory-blinded study in healthy toddlers, children, and teenagers designed to investigate the safety, reactogenicity, and immunogenicity of an inactivated influenza H1N1 vaccine (AdimFlu-S).
- Trial name
- NCT01007201
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- 2 sites in Taiwan
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Chronic Hepatitis B
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Trial name
- NCT00057265
- Testing
- telbivudine or lamivudine
- Where
- 11 sites in United States, South Korea and 4 more
- Sponsor
- Novartis
Metastatic Cancer, Epithelial Tumor
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
- Trial name
- STAR (NCT04053283)
- Testing
- NG-641
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Akamis Bio
COVID-19, Influenza A
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06734741
- Testing
- COVID/Flu Detect™ Rapid Self-Test
- Where
- 10 sites in United States
- Volunteers
- 899 people
- Sponsor
- InBios International, Inc.
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
Therapeutic Hepatitis C Virus Vaccine
GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax™) in chronic HCV patients.
- Trial name
- NCT04318379
- Testing
- HCVax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GeneCure Biotechnologies
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Treatment of Acute Yellow Fever Virus Infection
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Yellow Fever is an acute viral hemorrhagic disease caused by the Yellow Fever Virus (YFV), a re-emerging arbovirus transmitted by the same mosquito vector (Aedes aegypti) that transmits Dengue virus (DENV) and Zika virus (ZIKV).
- Trial name
- NCT03776786
- Testing
- TY014, 0.9% Saline
- Where
- Singapore
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tysana Pte Ltd
SARS-CoV-2, Influenza
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS…
- Trial name
- NCT06097273
- Testing
- mRNA-1083, Influenza Vaccine, COVID-19 Vaccine
- Where
- 146 sites in United States
- Volunteers
- 8,061 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.